IMVT News and Press, Immunovant Inc. From 04/02/24

2024-04-02 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling no...

2024-02-12 07:08:54 ET More on Immunovant Immunovant: An Intriguing And Developing Story Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Immunovant stock jumps 9% on positive data for Graves' disease drug Immunovant gains after Phase 1 d...

Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal years Initial period 1 data from Phase 2b clinical trial of batoclimab in chron...

Asics Corporation ADR (ASCCY) is expected to report for quarter end 2023-12-31 W. P. Carey Inc. REIT (WPC) is expected to report $1.16 for Q4 2023 Core Scientific, Inc. (CORZQ) is expected to report for Q4 2023 Essent Group Ltd. (ESNT) is expected to report $1.59 for Q4 2023 SAAB ...

Atlas Lithium Corporation (ATLX) is expected to report $-0.47 for Q4 2023 Capital Product Partners L.P. (CPLP) is expected to report $0.7 for Q4 2023 WisdomTree Inc. (WT) is expected to report $0.11 for Q4 2023 Mitsubishi Corporation (MSBHF) is expected to report for Q3 2024 C3is ...

2024-02-01 07:22:58 ET Summary Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN patients, putting this candidate on investors' radars ...

2024-01-27 04:45:00 ET Summary Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP Founder Class returned 1.1% for the Fourth Quarter of 2023 and 8.8% for the full year. The fund has returned...

2024-01-25 09:32:10 ET Summary Today, we take a deeper look at Immunovant, Inc., a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for autoimmune diseases. The stock has been on a big run since last summer, as its primary pipeline asset is bein...

2024-01-21 02:50:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2023, Baron Health Care Fund® (the Fund) advanc...